Valiant Organics Q2 revenue rises 93.4%, margin falls 515 bps
Key highlights
- Valiant Organics reported Q2 FY27 revenue from operations of Rs 304.2 crore, up 93.4% year-on-year.
- Q2 FY27 operating EBITDA margin was 12.82%, down 515 basis points from 17.97% in Q1 FY27.
- Hydrogenation generated Rs 174.4 crore, or 56% of Q2 FY27 revenue, after a 37% sequential increase.
- H1 FY27 consolidated EBITDA rose 75.6% to Rs 80.6 crore and margin increased 235 basis points to 15.04%.
powered by IRIS

In Q2 FY27, Valiant Organics Limited reported Rs 304.2 crore of revenue from operations, up 93.4% year-on-year, while operating EBITDA margin fell 515 basis points quarter-on-quarter to 12.82% as raw-material costs rose faster than realisations. Sales volumes rose 28% sequentially, while earnings before interest, tax, depreciation and amortisation (EBITDA) declined 6.3% to Rs 39 crore.
Know Valiant Organics inside out
Results, valuation, peers and who's buying, in one view.
Why did Valiant Organics' Q2 FY27 revenue rise 93.4%?
Valiant Organics' Q2 FY27 revenue rose because sales volumes increased 43% year-on-year and 28% quarter-on-quarter across all chemistries. Revenue from operations reached Rs 304.2 crore, compared with Rs 157.3 crore in Q2 FY26 and Rs 231.5 crore in Q1 FY27. The year-on-year rise of 93.4% was accompanied by a 31.4% sequential revenue increase.
The company reported that every chemistry recorded higher volume than in Q1 FY27, although revenue movement varied by product group. Total expenses rose 94.9% year-on-year to Rs 265.2 crore, marginally faster than revenue, and increased 39.7% sequentially, faster than the 31.4% increase in quarterly revenue. This cost pattern explains why the revenue increase did not produce a proportionate gain in quarterly operating profit.
At the operating level, EBITDA was Rs 39 crore in Q2 FY27, against Rs 21.2 crore a year earlier. That was an 84.0% year-on-year increase, but it was below the Rs 41.6 crore reported in Q1 FY27. The quarter therefore combined a much larger revenue base with a sequential decline in EBITDA.
Which chemistries drove Valiant Organics' Q2 FY27 growth?
Hydrogenation was Valiant Organics' largest Q2 FY27 revenue contributor, generating Rs 174.4 crore, or 56% of quarterly revenue, after a 37% sequential rise. The company attributed the increase to higher Para Amino Phenol output at Jhagadia Unit 2. Hydrogenation volume rose 27% quarter-on-quarter to 6,244 metric tonnes, compared with 4,916 metric tonnes in Q1 FY27.
Ammonolysis was the second-largest contributor at Rs 71.5 crore, with revenue increasing 50% quarter-on-quarter and volume rising 60% to 3,600 metric tonnes across Vapi and Tarapur. The company said this revenue increase occurred despite softer para nitroaniline, or PNA, realisations. Chlorination, by contrast, recorded only 4% sequential volume growth and lower revenue as chlorophenol realisations fell and phenol costs increased.
Chlorination revenue declined to Rs 43.8 crore in Q2 FY27 from Rs 45.1 crore in Q1 FY27, despite volume reaching 2,719 metric tonnes from 2,623 metric tonnes. Hydrogenation and ammonolysis supplied the principal sequential revenue increases, while revenue from acetylation and sulphonation, included in others, rose 44% to Rs 20.3 crore on a richer specialty mix. In the H1 FY27 volume mix, hydrogenation represented 49%, ammonolysis 25%, chlorination 23% and others 3%.
Got a follow-up? Ask IRIS
Why did Valiant Organics' EBITDA margin decline sequentially?
Valiant Organics' operating EBITDA margin declined because raw-material costs rose faster than realisations, according to the company. The margin was 12.82% in Q2 FY27, down from 17.97% in Q1 FY27, a fall of 515 basis points, where 100 basis points equal one percentage point. It was also 66 basis points below the 13.48% reported in Q2 FY26.
The effect is visible in the sequential relationship between expenses and sales. Revenue increased by Rs 72.7 crore from Q1 FY27 to Rs 304.2 crore in Q2 FY27, whereas total expenses increased by Rs 75.3 crore to Rs 265.2 crore. As a result, EBITDA decreased by Rs 2.6 crore to Rs 39 crore, despite the revenue expansion and 28% sequential volume growth.
Chlorination illustrates the pressure from both input costs and selling prices. Its Q2 FY27 revenue was Rs 43.8 crore, lower than Rs 45.1 crore in Q1 FY27, while the company identified lower chlorophenol realisations and higher phenol costs. Other income also declined to Rs 1.1 crore from Rs 3.3 crore in Q1 FY27, while finance cost was broadly stable at Rs 5.2 crore versus Rs 5.1 crore.
The sequential squeeze extended below EBITDA. Consolidated profit before tax was Rs 24.8 crore in Q2 FY27, down from Rs 36.8 crore in Q1 FY27, partly as the share of profit from associates fell to Rs 0.2 crore from Rs 7.2 crore. Profit after tax, or PAT, was Rs 17.3 crore, down 41.0% quarter-on-quarter from Rs 29.3 crore, and PAT margin declined 697 basis points to 5.69%.
How did Valiant Organics perform in H1 FY27?
Valiant Organics' H1 FY27 consolidated performance improved from H1 FY26, with revenue from operations rising 48.1% to Rs 535.8 crore and EBITDA increasing 75.6% to Rs 80.6 crore. The H1 operating EBITDA margin reached 15.04%, up 235 basis points from 12.69% in H1 FY26. This half-year comparison differs from Q2 alone, where the margin contracted both sequentially and modestly year-on-year.
H1 FY27 total expenses increased 44.1% to Rs 455.2 crore, slower than the 48.1% revenue increase, allowing the half-year EBITDA margin to expand. Consolidated PAT was Rs 46.6 crore, compared with Rs 13.9 crore in H1 FY26, while PAT margin rose to 8.70% from 3.84%. Basic and diluted earnings per share were Rs 16.22, against Rs 4.95 a year earlier.
The consolidated half-year result also included Rs 7.4 crore as the share of profit of associates, compared with Rs 0.7 crore in H1 FY26. Finance cost was Rs 10.3 crore, broadly unchanged from Rs 10.2 crore, while depreciation increased 6.8% to Rs 20.5 crore. These reported items contributed to profit before tax of Rs 61.6 crore, compared with Rs 18.5 crore in the prior-year half.
Valiant Organics spent Rs 26.3 crore on capital expenditure in H1 FY27, mainly for Sarigam and its two Jhagadia units. The presentation identifies the spending areas but does not provide a completion date, capacity figure or financial return target for these projects. The reported H1 figures therefore show higher revenue and profit, while the Q2 result shows that input-cost and realisation movements can affect quarterly conversion.
Conclusion
Valiant Organics delivered sharply higher Q2 FY27 revenue and volume, led by hydrogenation and ammonolysis, but expenses rose faster than sales from Q1 FY27. Revenue of Rs 304.2 crore was 93.4% above Q2 FY26, while operating EBITDA of Rs 39 crore was 84.0% higher year-on-year and 6.3% lower sequentially, producing a 12.82% margin.
The next disclosed item to watch is the deployment of Rs 26.3 crore of H1 FY27 capital expenditure at Sarigam and the two Jhagadia units, alongside the quarterly direction of raw-material costs and product realisations. The presentation does not disclose a completion timetable, capacity addition or return target for these projects, leaving subsequent operating updates relevant to assessing their effect.


